Every one of those 2 sits in a single category, market-trends. Alignment Healthcare is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Across an 18-day span, the pace is roughly 0.8 stories per week. Each story carries 5 original sources on average, compared with 3.4 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Baird
Every one of those 2 sits in a single category, market-trends. Alignment Healthcare is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Across an 18-day span, the pace is roughly 0.8 stories per week. Each story carries 5 original sources on average, compared with 3.4 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 5.8. We currently track 2 Healthcare stories that mention Baird, published between February 25, 2026 and March 14, 2026.
Stories tracked
2
Per week
0.8
Sources per story
5
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 358 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Baird. Shared-story counts are live from our verified record — not editorial picks.
Alignment Healthcare (NASDAQ: ALHC) has reported significant insider selling, including a 29,113-share disposal by its President, shortly after a major secondary offering. These transactions occur as the company navigates a shift in analyst sentiment and a challenging regulatory environment for Medicare Advantage providers.
Alignment Healthcare (ALHC) is set to report its fourth-quarter results, with investors focusing on membership growth and the medical loss ratio (MLR) within its tech-enabled Medicare Advantage platform. As the MA market faces regulatory headwinds, ALHC's ability to maintain clinical outcomes through its proprietary AVA software remains a critical differentiator.
Baird is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.